|
|
Originally posted by: JAB
Cathy, to my knowledge, the most recent study is:
http://alzheimers.boomja.com/A...edicines-192776.html
Everything I've found since then either discusses the possible mechanisms underlying the potential benefits of these two classes of antihypertensives, or they critique or defend the study designs, e.g.:
http://www.bmj.com/content/340/bmj.b5409.full
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2981427/
http://www.amjmed.com/article/...0%2900846-6/fulltext
http://www.medscape.com/viewarticle/727160
http://www.nature.com/nrcardio...cardio.2010.161.html
http://www.sanp.ch/pdf/2011/2011-03/2011-03-108.PDF
http://onlinelibrary.wiley.com...41.2010.02490.x/full
Results imply that both classes of meds may be effective for slowing progression as well as for preventing or delaying the onset of dementia.
Among the best studied ARBs are candesartan, losartan and telmisartan (listed alphabetically, not in order of strength of supporting data). There is some reason to believe that a combination therapy of an ARB and a centrally-active ACE, and possibly a calcium-channel blocker such as nitrendipine, would be optimum.
|
Joined: 1/14/2015
Posts: 40463
|
Originally posted by: Cathy J. M.
Have read that certain ACE inhibitors, the centrally-acting kind that cross the blood-brain barrier, minimize the risk of cognitive problems. Later studies seem to favor ARBs. Anyone know which is now considered better?
Minimizing the risk of AD is different from decreasing cognitive decline in someone who has it. Any evidence that either type does this?
I can do more research on this myself, and can ask our geriatrician (who specializes in memory loss and dementia) -- but I thought someone here might already know.
|
|
|
Originally posted by: Rose_Ro
I wonder...one of the meds which worked ''best'' for my mom gave her terrible back pains...didn't even connect it in the beginning..
|